Tag Archives: RAD001

mTOR inhibitor Everolimus RAD001 joined with vinorelbine and trastuzumab with regard to patients with breast area cancer

To determine the probable dose and schedule for everolimus, an oral everolimus mTOR inhibitor, joined with vinorelbine and trastuzumab with regard to patients with  HER2-overexpressing metastatic breast area cancer pretreated with trastuzumab. Within this phase Ib multicenter everolimus, Bayesian dose-escalation … Continue reading

Posted in inhibitors | Tagged , , | Leave a comment

RAD001 is an investigational once-daily oral therapy

Proof-of-concept studies presented at ASCO 2008 show RAD001 could offer you a novel remedy method for breast cancer by enhancing the efficacy of and overcoming resistance to various typically made use of breast cancer treatments. Findings from a Phase II … Continue reading

Posted in Uncategorized | Tagged | Leave a comment